Bioactive Products
| A unique collection of 552 Anti-inflammatory natural compound library for Anti-inflammatory screening and New Anti-inflammatory drug research | ||
| Catalog No: | B72a26 | Anti-inflammatory Compound Library Screening Details |
| Size: | 1mg/well * 552 Compounds 2mg/well * 552 Compounds | |
| Cat. No. | Information |
| CFN90192 | 1,2,3,4,6-O-Pentagalloylglucose 1,2,3,4,6-O-Pentagalloylglucose(PGG) has antimutagenic, anti-proliferative, anti-invasive,vasodilatory, anti-inflammatory, anti-parasitic, anti-HBV, and antioxidant activities. PGG may serve as a model for the development of new types of anti-diabetic and anti-metabolic syndrome therapeutics. PGG dilates vascular smooth muscle and suppresses the vascular inflammatory process via endothelium-dependent nitric oxide (NO)/cGMP signaling; it also has inhibition of inducible NO synthase and cyclooxygenase-2 activity. |
| CFN90201 | Allicin Allicin exerts antioxidant, bactericidal, anti-cancer, anti-inflammatory activities, it exerts an inhibitory immunomodulatory effect on intestinal epithelial cells. Allicin could significantly inhibit vascular smooth muscle cells' proliferation and migration induced by insulin, which may be related to the inhibition of the activation of ERK signal path. Allicin is beneficial in reducing blood cholesterol, triglycerides levels and systolic blood pressure in hypercholesterolemic rats, it may beneficially affect two risk factors for atherosclerosis–hyperlipidemia and hypertension. |
| CFN90203 | Sulforaphane Sulforaphane is a cruciferous vegetable-derived isothiocyanate with promising antitumor, chemopreventive and therapeutic activities, it inhibits TPA-induced NF-κB activation and COX-2 expression in MCF-10A cells by blocking two distinct signaling pathways mediated by ERK1/2-IKKα and NAK-IKKβ. Sulforaphane may exert a significant neuroprotective effect on cholinergic deficit and cognitive impairment, it also has anti-inflammatory effect, at least ,in part,associated with interfering with the NF-κB pathway. |
| CFN90207 | Glaucocalyxin A Glaucocalyxin A could potentially be developed as an antiplatelet and antithrombotic agent, can inhibit platelet p-selectin secretion and integrin activation by convulxin, is a GPVI selective ligand. Glaucocalyxin A has regulation of microglia activity, can attenuate lipopolysaccharide -stimulated neuroinflammation through NF-κB and p38 MAPK signaling pathways.Glaucocalyxin A may become a potential anti-fibrotic agent in Idiopathic pulmonary fibrosis (IPF) management, it can effectively ameliorate pulmonary fibrosis through the antagonism of leukocyte infiltration and proinflammatory cytokine production. |
| CFN90210 | Diosmetin Diosmetin has anti-osteoporosis, cytoprotective, antibacterial, anti-pigmentation, anti-inflammatory and antioxidant properties, it induces osteoblastic differentiation through the PKCδ-Rac1-MEK3/6-p38 and PKCδ-Rac1-MEK1/2- ERK1/2-Runx2 pathways.Diosmetin has intracellular antioxidant detoxifying effect, the mechanism is associated with both nonenzymatic and enzymatic defense systems.Diosmetin and luteolin exert synergistic cytostatic effects in human hepatoma HepG2 cells via CYP1A-catalyzed metabolism, activation of JNK and ERK and P53/P21 up-regulation. |
